The FDA established Category 1 as part of the evaluation process for substances that may be eligible for compounding while additional data is reviewed regarding safety, characterization, and clinical considerations. In recent years, several peptides have undergone review as part of the FDAs evaluation of drug substances, with the agency citing the need for additional information regarding characterization and safety data before determining long-term eligibility for compounding. Regulatory and industry discussions continue regarding whether certain peptides may be reconsidered as additional data becomes available, reflecting continued evaluation of clinical interest alongside safety oversight considerations. Recent coverage indicates the FDA is expected to convene expert panels to review whether broader access to certain peptides may be appropriate within regulated compounding frameworks, highlighting the ongoing evolution of peptide-related regulatory guidance. Because regulatory status may evolve, providers often monitor updates to ensure treatment decisions align with current guidance and applicable compounding standards
J Clin Invest 1996;98:70-77
A thoughtful plan looks at the whole metabolic networkdiet quality, liver support, antioxidant balance, and the realities of agingrather than chasing one lab-sounding ingredient
Patients often notice increased reactivity to foods, chemicals, and environmental triggers that didnt previously bother them
DOI:10.1016/j.redox.2015.09.009 58
